Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;17(5):472-482.
doi: 10.1177/1740774520939938. Epub 2020 Jul 16.

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Affiliations
Review

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Lori E Dodd et al. Clin Trials. 2020 Oct.

Abstract

Background: Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information. COVID-19 presentation is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks to over a month and can end in death. While improvement in mortality would provide unquestionable evidence about the clinical significance of a treatment, sample sizes for a study evaluating mortality are large and may be impractical, particularly given a multitude of putative therapies to evaluate. Furthermore, patient states in between "cure" and "death" represent meaningful distinctions. Clinical severity scores have been proposed as an alternative. However, the appropriate summary measure for severity scores has been the subject of debate, particularly given the variable time course of COVID-19. Outcomes measured at fixed time points, such as a comparison of severity scores between treatment and control at day 14, may risk missing the time of clinical benefit. An endpoint such as time to improvement (or recovery) avoids the timing problem. However, some have argued that power losses will result from reducing the ordinal scale to a binary state of "recovered" versus "not recovered."

Methods: We evaluate statistical power for possible trial endpoints for COVID-19 treatment trials using simulation models and data from two recent COVID-19 treatment trials.

Results: Power for fixed time-point methods depends heavily on the time selected for evaluation. Time-to-event approaches have reasonable statistical power, even when compared with a fixed time-point method evaluated at the optimal time.

Discussion: Time-to-event analysis methods have advantages in the COVID-19 setting, unless the optimal time for evaluating treatment effect is known in advance. Even when the optimal time is known, a time-to-event approach may increase power for interim analyses.

Keywords: COVID-19; WHO ordinal scale; censoring; clinical trials; endpoints; log-rank test; proportional odds model.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Ordinal outcome values by day of study from 100 simulated trajectories from the reference scenario. The smooth lines represent the average trajectories, while the bent lines represent the observed scores for individual patients.

Comment in

References

    1. National Institutes of Health. [accessed 12 May 2020];COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020 https://www.covid19treatmentguidelines.nih.gov/ - PubMed
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. - PMC - PubMed
    1. Sellner J, Taba P, Oztürk S, et al. The need for neurologists in the care of COVID-19 patients. Eur J Neurol. doi: 10.1111/ene.14257. Epub ahead of print 23 April 2020. - DOI - PMC - PubMed
    1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. - PMC - PubMed
    1. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: results of a randomized, double-blind, placebo-controlled, multicenter trial. Lancet. 2020;395:1569–1578. - PMC - PubMed

Publication types

Substances

LinkOut - more resources